International Guideline Harmonization Group
  • Home
  • About IGHG
    • Members
      • Core group
      • Guideline panels
        • Bone mineral density
        • Breast cancer
        • Cardiomyopathy
        • Central nervous system neoplasms
        • Colorectal cancer
        • Coronary artery disease
        • Dexrazoxane cardioprotection
        • Fatigue, mental health and psychosocial problems
        • Fertility preservation
        • Growth hormone treatment
        • Health promotion
        • Hepatic toxicity
        • Hypothalamic-pituitary dysfunction
        • Male gonadotoxicity
        • Metabolic syndrome
        • Nephrotoxicity
        • Neurocognitive problems
        • Obstetric care
        • Ototoxicty
        • Premature ovarian insufficiency
        • Pulmonary dysfunction
        • Splenic dysfunction
        • Thyroid cancer
        • Thyroid dysfunction
        • Anthracycline cardiotoxicity equivalence ratio
        • COVID-19 Statement
    • Collaborators
    • Funding sources
    • Methods
      • Process
      • Grading system
      • Topic selection
      • Publication
      • Handbook
  • Guidelines
    • Topics
      • Bone mineral density
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Breast cancer
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Cardiomyopathy
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Central nervous system neoplasms
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Colorectal cancer
        • Guideline panel
      • Coronary artery disease
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Dexrazoxane cardioprotection
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Fatigue
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Fertility preservation
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publications
        • Guideline panel
      • Growth hormone treatment
        • Guideline panel
      • Health promotion
        • Guideline panel
      • Hepatic toxicity
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Hypothalamic-pituitary dysfunction
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Male gonadotoxicity
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Mental health problems
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Metabolic syndrome
        • Guideline panel
      • Nephrotoxicity
        • Guideline panel
      • Neurocognitive problems
        • Guideline panel
      • Obstetric care
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Ototoxicity
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Premature ovarian insufficiency
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Psychosocial problems
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Pulmonary dysfunction
        • Guideline panel
      • Splenic dysfunction
        • Guideline panel
      • Thyroid cancer
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Thyroid dysfunction
        • Guideline panel
      • Anthracycline cardiotoxicity equivalence ratio
        • Guideline panel
      • COVID-19 Statement
  • Patient education
  • News
  • Meetings
  • Contact

News

Home News

News archive

  • June 2023
  • March 2023
  • November 2022
  • May 2022
  • March 2021
  • October 2020
  • September 2020
  • April 2020
  • February 2019
  • January 2017
  • August 2016
  • July 2016
  • April 2015
  • September 2014
  • October 2013
  • June 16, 2023

    New published guidelines

    The following guidelines have been published:

    • Dexrazoxane cardioprotection recommendations for children with cancer in The Lancet Child & Adolescent Health
    • Updated cardiomyopathy surveillance recommendations in the Lancet Read more
  • November 24, 2022

    ISLCCC 2023

    Save the date: June 15-17, 2023!
    International Symposium on Late Complications after Childhood Cancer (ISLCCC)

    Plan to join us in person for the second ISLCCC meeting, which will convene on June 15-17, Read more

  • May 29, 2022

    New guidelines published

    The following guidelines have been published:

    • Psychosocial problems surveillance in Cancer
    • Mental health problems surveillance in The Lancet Oncology
    • Coronary artery disease surveillance in European Journal Read more
  • May 18, 2022

    International Symposium on Late Complications after Childhood Cancer – ISLCCC 2022

    On 7-9 July 2022 the first ISLCCC meeting was convened at the Princess Read more

  • March 15, 2021

    Kick off expert panel splenic dysfunction

    We will soon initiate the harmonization of the splenic dysfunction surveillance guideline. Please contact us if you are interested in participating in this guideline panel.

    Read more
  • October 21, 2020

    New guidelines published

    The following guidelines have been published or accepted for publication:

    • Updated breast cancer surveillance recommendations in the Journal of Clinical Oncology
    • Obstetric care recommendations in the American Journal Read more
  • September 01, 2020

    The impact of COVID-19 on survivorship care: an IGHG questionnaire study

    The IGHG COVID-19 working group is currently researching how the outbreak of COVID-19 has impacted the delivery of survivorship care for survivors of childhood, adolescent and young adult cancer. In this Read more

  • April 07, 2020

    IGHG COVID-19 Statement

    Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus.

    The IGHG COVID-19 working group developed a statement to provide guidance to childhood, adolescent and young adult Read more

  • March 16, 2023

    Minutes IGHG meeting June 2022

    Minutes IGHG meeting June 2022Download
      Read more
    1234567
    • Contact
    • Disclaimer

    © International Guideline Harmonization Group